Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

• Published in: Clinical pharmacokinetics 2024-02, Vol.63 (2), p.171-182
• Main Authors: Chen, Joseph, Bearz, Alessandra, Kim, Dong-Wan, Mamdani, Hirva, Bauman, Jessica, Chiari, Rita, Ou, Sai-Hong Ignatius, Solomon, Benjamin J, Soo, Ross A, Felip, Enriqueta, Shaw, Alicet, Thurm, Holger, Clancy, Jill S, Lee, Kimberly, O'GOrman, Melissa, Tanski, Cherie, Pithavala, Yazdi K
• Format: Article
• Language: English
• Subjects: Analgesics; Cancer therapies; Cytochrome; Drug dosages; Enzymes; FDA approval; Glycoproteins; Kinases; Lung cancer; Lymphoma; Metabolism; Metabolites; Pharmacokinetics; Plasma; Prescription drugs
• ISSN: 0312-5963; 1179-1926
• DOI: 10.1007/540262-023-01309-4

Background and Objective Lorlatinib is a tyrosine kinase inhibitor approved for the treatment of advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. This study assessed the effect of steady-state lorlatinib on the metabolic enzymes cytochrome P450 (CYP) 2B6, CYP2C9, and uridine 5'-diphospho-glucuronosyltransferase (UGT) and the P-glycoprotein (P-gp) transporter.Methods Thirty-two patients received a single oral dose of a probe drug on Day - 2 to determine the pharmacokinetics of the probe drug alone. Starting on Day 1, patients received 100 mg oral lorlatinib daily. On Day 15, a single oral dose of the probe drug was administered concurrently with lorlatinib. Pharmacokinetic parameters for these probe substrates were assessed. Results Plasma exposures of all probe substrates were reduced by lorlatinib compared with the probe alone. The greatest reduction in area under the plasma concentration-time curve from time zero to infinity (AUC^,) and maximum (peak) plasma drug concentration (Cmax) (67% and 63% decrease, respectively) was observed with the P-gp probe substrate fexofenadine. Lorlatinib coadministration also decreased the AUC^, and Cmax of bupropion (CYP2B6 probe substrate) by 25% and 27%, tolbutamide (CYP2C9 probe substrate) by 43% and 15%, and acetaminophen (UGT probe substrate) by 45% and 28%, respectively.Conclusions Lorlatinib is a net moderate inducer of P-gp and a weak inducer of CYP2B6, CYP2C9, and UGT after steady state is achieved with daily dosing. Medications that are P-gp substrates with a narrow therapeutic window should be avoided in patients taking lorlatinib; no dose modifications are needed with substrates of CYP2B6, CYP2C9, or UGT.